Industry praises EU move on orphan drugs and rare diseases
This article was originally published in Scrip
Executive Summary
The European Commission's strategy on rare diseases, which is intended to ensure that all patients with rare diseases have access to high-quality diagnosis and treatment, has been greeted with enthusiasm by the biopharmaceutical industry.